Home › Companies › STOKE THERAPEUTICS INC. › 2024-2025

STOKE THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and STOKE THERAPEUTICS INC.’s Form 8-K, filed 2025-06-04 (Item 5.07 on EDGAR). Page generated 02 October 2026.

7Reported items
135Asset managers
1,151Fund votes
2025-06-03Meeting date

Proxy season: 2024-2025 2025-2026

Explore STOKE THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by STOKE THERAPEUTICS INC.

These tallies are STOKE THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-04 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

STOKE THERAPEUTICS INC. — official shareholder meeting results, meeting held 2025-06-03
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Edward M. Kaye, M.D.	29,220,313	--	--	4,224,823	5,350,616	Majority: yes
Elect Director: Seth L. Harrison, M.D.	29,269,703	--	--	4,175,433	5,350,616	Majority: yes
Elect Director: Arthur O. Tzianabos, Ph.D.	29,241,848	--	--	4,203,288	5,350,616	Majority: yes
Proposal 2: Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025:	38,678,091	67,754	49,907	49,907	--	Majority: yes
Proposal 3: Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 22, 2025:	30,543,514	2,882,907	18,715	18,715	5,350,616	Majority: yes

Source: STOKE THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-06-04 — read the filing on EDGAR.

How asset managers voted at the STOKE THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 135 asset managers that disclosed a STOKE THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of STOKE THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%

FOR: 30,543,514AGAINST: 2,882,907

STOKE THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Co”): 30,543,514 for, 2,882,907 against, per its Form 8-K filed 2025-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 54,595,714 outstanding shares: 56% for, 5% against (61% of the company cast a for/against vote).

The 134 asset managers below cast 88% of the shares they voted on this item FOR (29,497,078 for, 3,912,486 against).

FOR 88%12%

FOR: 29,497,078 (88.2%)AGAINST: 3,912,486 (11.7%)ABSTAIN: 26,737 (0.1%)

Largest asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at STOKE THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
RTW INVESTMENTS, LP	4,971,887	0	For
Lynx1 Capital Management LP	4,603,233	0	For
Redmile Group, LLC	4,444,281	0	For
Fidelity	430,976	3,795,568	Against
Vanguard	2,807,799	0	For
BlackRock	2,137,630	0	For
MARSHALL WACE, LLP	1,999,155	0	For
Siren, L.L.C.	1,932,396	0	For
Charles Schwab	620,458	0	For
GEODE CAPITAL MANAGEMENT, LLC	516,186	0	For
MPM BioImpact LLC	515,702	0	For
State Street	486,181	0	For
DAFNA Capital Management LLC	479,998	0	For
Granahan Investment Management, LLC	461,720	0	For
JACOBS LEVY EQUITY MANAGEMENT, INC	325,306	0	For
Dimensional	316,383	0	For
Opaleye Management Inc.	300,000	0	For
Cormorant Asset Management, LP	254,161	0	For
Birchview Capital, LP	210,004	0	For
Northern Trust	192,082	0	For
Citadel	118,746	0	For
Jackson National	116,210	0	For
Equitable	106,269	0	For
Wellington	98,852	0	For
Woodline Partners LP	91,881	0	For

Showing the 25 largest of 134 asset managers. See all 134 in the interactive database.

2. TO INDICATE, ON AN ADVISORY BASIS, THE PREFERRED FREQUENCY OF FUTURE STOCKHOLDER ADVISORY VOTES TO APPROVE THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

99.4% fund support · no official result

1 YEAR 55%ONE YEAR 43%

The 126 asset managers below cast 99.4% of the shares they voted on this item FOR (37,466 for, 216 against).

FOR: 37,466 (0.1%)AGAINST: 216 (0.0%)1 YEAR: 18,077,755 (55.4%)ONE YEAR: 14,164,233 (43.4%)THREE YEARS: 327,380 (1.0%)3 YEARS: 11,180 (0.0%)

Largest asset managers voting on “TO INDICATE, ON AN ADVISORY BASIS, THE PREFERRED FREQUENCY OF FUTURE STOCKHOLDER ADVISORY VOTES TO APPROVE THE” at STOKE THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
RTW INVESTMENTS, LP	0	0	0	0	One Year
Lynx1 Capital Management LP	0	0	0	0	1 Year
Redmile Group, LLC	0	0	0	0	1 Year
Fidelity	0	0	0	0	One Year
Vanguard	0	0	0	0	One Year
BlackRock	0	0	0	0	1 Year
MARSHALL WACE, LLP	0	0	0	0	1 Year
Siren, L.L.C.	0	0	0	0	1 Year
Charles Schwab	0	0	0	0	1 Year
GEODE CAPITAL MANAGEMENT, LLC	0	0	0	0	One Year
MPM BioImpact LLC	0	0	0	0	1 Year
State Street	0	0	0	0	One Year
DAFNA Capital Management LLC	0	0	0	0	1 Year
JACOBS LEVY EQUITY MANAGEMENT, INC	0	0	0	0	1 Year
Dimensional	0	0	0	0	Three Years
Cormorant Asset Management, LP	0	0	0	0	1 Year
Birchview Capital, LP	0	0	0	0	1 Year
Northern Trust	0	0	0	0	1 Year
Citadel	0	0	0	0	One Year
Jackson National	0	0	0	0	1 Year
Equitable	0	0	0	0	One Year
Wellington	0	0	0	0	1 Year
Woodline Partners LP	0	0	0	0	One Year
Nuveen	0	0	0	0	One Year
Victory Capital	0	0	0	0	One Year

Showing the 25 largest of 126 asset managers. See all 126 in the interactive database.

3. Election of Class III Directors to serve until the 2028 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: Arthur O. Tzianabos, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%13%

FOR: 29,241,848WITHHELD: 4,203,288

STOKE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Arthur O. Tzianabos, Ph.D.”): 29,241,848 for, 4,203,288 withheld, per its Form 8-K filed 2025-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 54,595,714 outstanding shares: 53.6% for, 8% withheld (61% of the company cast a for/withheld vote).

The 46 asset managers below cast 100% of the shares they voted on this item FOR (4,583,764 for, 0 against).

FOR 64%ABSTAIN 36%

FOR: 4,583,764 (64.4%)ABSTAIN: 2,538,550 (35.6%)

Largest asset managers voting on “Election of Class III Directors to serve until the 2028 annual meeting of stockholders or until their successo” at STOKE THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	2,713,712	0	For
Fidelity	430,976	1,846,841	Abstain
BlackRock	864,469	0	For
Charles Schwab	310,229	0	For
Dimensional	0	230,089	Abstain
Jackson National	0	116,210	Abstain
Equitable	65,639	40,630	For
TIAA	81,434	0	For
Victory Capital	0	78,813	Abstain
Lincoln Financial	0	51,781	Abstain
State Street	92	38,795	Abstain
QUANTITATIVE MASTER SERIES LLC	26,368	0	For
Northern Trust	26,257	0	For
ProShares	0	21,838	Abstain
Global X	21,138	0	For
Direxion Shares ETF Trust	0	18,423	Abstain
Brighthouse	0	11,723	Abstain
PFM Multi-Manager Series Trust	0	11,200	Abstain
Pacific Life	10,686	0	For
Nationwide	10,558	0	For
AIG/SunAmerica	0	10,414	Abstain
Voya	0	9,864	Abstain
ETFis Series Trust I	0	8,290	Abstain
Prudential/PGIM	0	7,930	Abstain
Bridge Builder Trust	6,905	0	For

Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.

4. Election of Class III Directors to serve until the 2028 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: Edward M. Kaye, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%13%

FOR: 29,220,313WITHHELD: 4,224,823

STOKE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Edward M. Kaye, M.D.”): 29,220,313 for, 4,224,823 withheld, per its Form 8-K filed 2025-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 54,595,714 outstanding shares: 53.5% for, 8% withheld (61% of the company cast a for/withheld vote).

The 46 asset managers below cast 100% of the shares they voted on this item FOR (4,512,387 for, 0 against).

FOR 63%ABSTAIN 37%

FOR: 4,512,387 (63.4%)ABSTAIN: 2,609,927 (36.6%)

Largest asset managers voting on “Election of Class III Directors to serve until the 2028 annual meeting of stockholders or until their successo” at STOKE THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	2,713,712	0	For
Fidelity	430,976	1,846,841	Abstain
BlackRock	864,469	0	For
Charles Schwab	310,229	0	For
Dimensional	0	230,089	Abstain
Jackson National	0	116,210	Abstain
Equitable	65,639	40,630	For
TIAA	0	81,434	Abstain
Victory Capital	0	78,813	Abstain
Lincoln Financial	0	51,781	Abstain
State Street	92	38,795	Abstain
QUANTITATIVE MASTER SERIES LLC	26,368	0	For
Northern Trust	26,257	0	For
ProShares	0	21,838	Abstain
Global X	21,138	0	For
Direxion Shares ETF Trust	0	18,423	Abstain
Brighthouse	0	11,723	Abstain
PFM Multi-Manager Series Trust	0	11,200	Abstain
Pacific Life	10,686	0	For
Nationwide	10,558	0	For
AIG/SunAmerica	0	10,414	Abstain
Voya	9,864	0	For
ETFis Series Trust I	0	8,290	Abstain
Prudential/PGIM	0	7,930	Abstain
Bridge Builder Trust	6,905	0	For

Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.

5. Election of Class III Directors to serve until the 2028 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: Seth L. Harrison, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%

FOR: 29,269,703WITHHELD: 4,175,433

STOKE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Seth L. Harrison, M.D.”): 29,269,703 for, 4,175,433 withheld, per its Form 8-K filed 2025-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 54,595,714 outstanding shares: 53.6% for, 8% withheld (61% of the company cast a for/withheld vote).

The 46 asset managers below cast 100% of the shares they voted on this item FOR (4,553,066 for, 0 against).

FOR 64%ABSTAIN 36%

FOR: 4,553,066 (63.9%)ABSTAIN: 2,569,248 (36.1%)

Largest asset managers voting on “Election of Class III Directors to serve until the 2028 annual meeting of stockholders or until their successo” at STOKE THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	2,713,712	0	For
Fidelity	430,976	1,846,841	Abstain
BlackRock	864,469	0	For
Charles Schwab	310,229	0	For
Dimensional	0	230,089	Abstain
Jackson National	0	116,210	Abstain
Equitable	65,639	40,630	For
TIAA	0	81,434	Abstain
Victory Capital	0	78,813	Abstain
Lincoln Financial	26,400	25,381	For
State Street	38,843	44	For
QUANTITATIVE MASTER SERIES LLC	26,368	0	For
Northern Trust	0	26,257	Abstain
ProShares	0	21,838	Abstain
Global X	21,138	0	For
Direxion Shares ETF Trust	0	18,423	Abstain
Brighthouse	0	11,723	Abstain
PFM Multi-Manager Series Trust	0	11,200	Abstain
Pacific Life	10,686	0	For
Nationwide	10,558	0	For
AIG/SunAmerica	0	10,414	Abstain
Voya	9,864	0	For
ETFis Series Trust I	0	8,290	Abstain
Prudential/PGIM	0	7,930	Abstain
Bridge Builder Trust	6,905	0	For

Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.

6. TO RATIFY THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 38,678,091AGAINST: 67,754

STOKE THERAPEUTICS INC.’s own tally for this item (“Proposal 2: Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025:”): 38,678,091 for, 67,754 against, per its Form 8-K filed 2025-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 54,595,714 outstanding shares: 71% for, 0.2% against (71% of the company cast a for/against vote).

The 46 asset managers below cast 100% of the shares they voted on this item FOR (7,122,314 for, 0 against).

FOR 100%

FOR: 7,122,314 (100.0%)

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR” at STOKE THERAPEUTICS INC., 2024-2025
Asset manager	For	Vote
Vanguard	2,713,712	For
Fidelity	2,277,817	For
BlackRock	864,469	For
Charles Schwab	310,229	For
Dimensional	230,089	For
Jackson National	116,210	For
Equitable	106,269	For
TIAA	81,434	For
Victory Capital	78,813	For
Lincoln Financial	51,781	For
State Street	38,887	For
QUANTITATIVE MASTER SERIES LLC	26,368	For
Northern Trust	26,257	For
ProShares	21,838	For
Global X	21,138	For
Direxion Shares ETF Trust	18,423	For
Brighthouse	11,723	For
PFM Multi-Manager Series Trust	11,200	For
Pacific Life	10,686	For
Nationwide	10,558	For
AIG/SunAmerica	10,414	For
Voya	9,864	For
ETFis Series Trust I	8,290	For
Prudential/PGIM	7,930	For
Bridge Builder Trust	6,905	For

Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.

7. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

— fund support · no official result

1 YEAR 91%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

ABSTAIN: 26,737 (5.3%)1 YEAR: 461,720 (91.3%)ONE YEAR: 17,023 (3.4%)

Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at STOKE THERAPEUTICS INC., 2024-2025
Asset manager	Abstain	Vote
Granahan Investment Management, LLC	0	1 Year
FORUM FUNDS II	26,737	Abstain
JPMorgan	0	One Year

Largest STOKE THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked by the number of STOKE THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 54,595,714 shares outstanding at the time of that meeting.

Top STOKE THERAPEUTICS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	RTW INVESTMENTS, LP	9.11%
2	Lynx1 Capital Management LP	8.43%
3	Redmile Group, LLC	8.14%
4	Fidelity	7.74%
5	Vanguard	5.14%
6	BlackRock	3.92%
7	MARSHALL WACE, LLP	3.66%
8	Siren, L.L.C.	3.54%
9	Charles Schwab	1.14%
10	GEODE CAPITAL MANAGEMENT, LLC	0.95%

Reported STOKE THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

STOKE THERAPEUTICS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Skorpios Trust	12.65%	DEF14A
RTW Investments, LP	10.88%	13G
BlackRock	10.74%	13F
Entities affiliated with RTW Investments, L.P.	9.73%	DEF14A
Lynx1 Capital Management LP	9.50%	DEF14A
Baker Bros. Advisors LP	8.00%	DEF14A
Redmile Group, LLC	7.63%	13G
Cowen Financial Products LLC	6.82%	DEF14A
Morgan Stanley	6.28%	13G
The Toronto-Dominion Bank	5.81%	13G

Percentages above are of 54,595,714 shares outstanding, as reported by STOKE THERAPEUTICS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from STOKE THERAPEUTICS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At STOKE THERAPEUTICS INC.'s shareholder meeting held 2025-06-03, in the 2024-2025 proxy season, 135 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,151 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. — FOR was 91% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: STOKE THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-04.

STOKE THERAPEUTICS INC. proxy season coverage: 2024-2025 (this page) · 2025-2026.